1333390-56-9

Basic information

• Product Name: Regorafenib iMpurity
• Synonyms: Regorafenib iMpurity;Regorafenib Monohydrate Impurity;Regorafenib Monohydrate IMP;Regorafenib Impurity 30
• CAS NO: 1333390-56-9
• Molecular Formula: C₁₄H₉ClF₄N₂O₂
• Molecular Weight: 348.68
• Mol File: 1333390-56-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 346.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.599±0.06 g/cm3(Predicted)
• PKA: 9.21±0.31(Predicted)
• CAS DataBase Reference: Regorafenib iMpurity(CAS DataBase Reference)
• NIST Chemistry Reference: Regorafenib iMpurity(1333390-56-9)
• EPA Substance Registry System: Regorafenib iMpurity(1333390-56-9)

Safety Data

• Hazardous Substances Data: 1333390-56-9(Hazardous Substances Data)

Usage

General Description

Regorafenib iMpurity, also known as 4-(4-Aminopyridin-1-yl)-1,2-dihydro-3H- cyclopenta [b]quinoline-2,6-dione, is a chemical compound that is commonly used as a reference standard in pharmaceutical research and development. This impurity is a potential byproduct or intermediate in the synthesis of Regorafenib, a medication used for the treatment of cancer. It is important to identify and quantify the levels of this impurity in pharmaceutical products to ensure the safety and efficacy of the final drug formulation. The chemical structure of Regorafenib iMpurity has been well-characterized, and it is widely available for purchase from various chemical suppliers for use in analytical testing and quality control in the pharmaceutical industry.

Upstream product

• 394-41-2 3-fluoro-4-nitrophenol 
• 320-51-4 4-chloro-3-trifluoromethyl-aniline 
• 777-37-7 4-chloro-3-(trifluoromethyl)nitrobenzene 
• 88-16-4 1-chloro-2-(trifluoromethyl)benzene 
• 65145-13-3 2-fluoro-4-hydroxybenzoic acid 
• 755037-03-7 regorafenib 

Downstream Products

• 755037-03-7 regorafenib 
• 1333386-18-7 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)-3-fluorophenoxy)-2-(N-1',1',1'-trideuteromethyl)pyridine amide p-toluenesulfonate 
• 1333390-47-8 C₂₁H₁₂⁽²⁾H₃ClF₄N₄O₃*CH₄O₃S 
• 1333488-98-4 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluoro-phenoxy)-N-(methyl-d₃)picolinamide hydrochloride 
• 1333489-03-4 C₂₁H₁₂⁽²⁾H₃ClF₄N₄O₄ 
• 1255386-16-3 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)-3-fluorophenoxy)-2-(N-1',1',1'-trideuteromethyl)pyridine amide 

Relevant articles and documents

Regorafenib analogues and their ferrocenic counterparts: Synthesis and biological evaluation

Approved by the FDA in 2012, regorafenib is one of the last chance treatments for colorectal cancer. While various analogues have already been prepared, ferrocenic derivatives have never been evaluated. In this study, we prepared various ferrocene-containing derivatives of regorafenib and recorded their biological activity in kinase and cellular assays. This led to the identification of a squaramide derivative which shows a good cellular activity and three ferrocene analogues with promising activity in both kinase and cellular assays. This journal is

Direct conversion of carboxylic acids to various nitrogen-containing compounds in the one-pot exploiting curtius rearrangement

Herein we report, a single-pot multistep conversion of inactivated carboxylic acids to various N-containing compounds using a common synthetic methodology. The developed methodology rendered the use of carboxylic acids as a direct surrogate of primary amines, for the synthesis of primary ureas, secondary/tertiary ureas, O/S-carbamates, benzoyl ureas, amides, and N-formyls, exploiting the Curtius reaction. This approach has a potential to provide a diversified library of N-containing compounds, starting from a single carboxylic acid, based on the selection of the nucleophile.

SORAFENIB ANALOGS AND USES THEREOF

The present invention provides, inter alia, compounds according to formula I. Also provided are pharmaceutical compositions and kits containing such compounds. Methods for using such compounds, compositions, and kits for treating a subject having system xc-, dysregulation for activating ferroptosis, for inhibiting system xc- in a cell, and for monitoring treatment of a subject having system xc- dysregulation are provided as well.